Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acute psychosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    40 result(s) found for: Acute psychosis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-004893-84 Sponsor Protocol Number: CBD-P Start Date*: 2019-08-22
    Sponsor Name:Mental Health Center Glostrup
    Full Title: Cannabidiol for treatment of non-affective psychosis and cannabis use
    Medical condition: Non-affective psychosis and lifetime cannabis use
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10037234 Psychosis LLT
    21.1 100000004869 10070996 Cannabis use LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000465-31 Sponsor Protocol Number: CannaBiD Start Date*: 2016-06-29
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression
    Medical condition: Bipolar disorder, current episode depressed
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10004936 Bipolar depression LLT
    19.0 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    19.0 10037175 - Psychiatric disorders 10026756 Manic depressive illness LLT
    19.0 10037175 - Psychiatric disorders 10026755 Manic depressive LLT
    19.0 10037175 - Psychiatric disorders 10004911 Bipolar affective disorder, depressed LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000118-31 Sponsor Protocol Number: CCTU0145 Start Date*: 2017-01-16
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2)
    Medical condition: Antibody associated Psychosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-010276-16 Sponsor Protocol Number: F1D-MC-HGMX Start Date*: 2009-11-19
    Sponsor Name:Eli Lilly
    Full Title: A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
    Medical condition: Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    13.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002787-32 Sponsor Protocol Number: RG_19-172 Start Date*: 2020-11-16
    Sponsor Name:University of Birmingham
    Full Title: Antidepressant for the prevention of DEPression following first episode Psychosis trial
    Medical condition: Patients with First Episode Psychosis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-006426-26 Sponsor Protocol Number: D1443L00009 Start Date*: 2007-01-17
    Sponsor Name:AstraZeneca AB
    Full Title: FAST – A randomised, open-label, parallel, multicentre Phase IIIb Study to evaluate the Efficacy and Safety of Quetiapine IR titrared over 4 Days in Patients with Acute Psychosis (Rapid versus Conv...
    Medical condition: Patients requiring treatment, as judged by the Investigator, for an acute episode of schizophrenia, schizoaffective disorder, psychosis NOS or bipolar mania (according to DSM-IV criteria).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015629-35 Sponsor Protocol Number: R076477SCH3038 Start Date*: 2009-11-05
    Sponsor Name:Janssen-Cilag NV/SA
    Full Title: Open-label, single arm, interventional study to explore the efficacy and safety of paliperidone ER in the management of patients with acute agitation and/or aggression
    Medical condition: Subject presenting with acute agitation and/or agression in the context of psychosis, suspected schizophrenia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016715-38 Sponsor Protocol Number: TEAprotocolversion3-12102009FINAL Start Date*: 2010-02-08
    Sponsor Name:University of Copenhagen
    Full Title: The TEA Trial- Tolerance and Effect of Antipsychotics in children and adolescents with psychosis An investigator-initiated, phase IV, randomised double-blind multi-centre trial of the benefits and...
    Medical condition: non-organic and non-drug-induced psychosis, meeting the criteria for ICD-10 diagnoses: F20, F22-F29 and F30.2, F31.2, F31.5, F32.3 and F33.3.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10032314 Other nonorganic psychoses LLT
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    16.1 10037175 - Psychiatric disorders 10004916 Bipolar affective disorder, depressed, severe degree, specified as with psychotic behavior LLT
    16.1 10037175 - Psychiatric disorders 10025460 Major depressive disorder, recurrent episode, severe degree, specified as with psychotic behaviour LLT
    16.1 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    16.1 10037175 - Psychiatric disorders 10025468 Major depressive disorder, single episode, severe degree, specified as with psychotic behavior LLT
    16.1 10037175 - Psychiatric disorders 10046122 Unspecified psychosis LLT
    16.1 10037175 - Psychiatric disorders 10026780 Manic psychosis LLT
    16.1 10037175 - Psychiatric disorders 10012255 Delusional disorder, unspecified type PT
    16.1 10037175 - Psychiatric disorders 10051988 Acute and transient psychotic disorder LLT
    16.1 10037175 - Psychiatric disorders 10004924 Bipolar affective disorder, manic, severe degree, specified as with psychotic behavior LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000766-23 Sponsor Protocol Number: D1443C00018 Start Date*: 2008-12-22
    Sponsor Name:Medical School Hannover, Department of Psychiatry, Socialpsychiatry and Psychotherapy
    Full Title: Effects of QuetiapineXR in schizophrenic patients with cannabis abuse and/or cannabis induced psychosis -pilot study-
    Medical condition: cannabis induced psychosis/schizophrenic patients with cannabis abuse
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005399-16 Sponsor Protocol Number: ROAC2014 Start Date*: 2014-08-05
    Sponsor Name:Dr. Benedicto Crespo. Servicio Psiquiatría. Hospital Universitario Marqués de Valdecilla/IDIVAL
    Full Title: Randomized, flexible-dose, open-label comparison to investigate the effectivenes of second generation antipsychotics in first episode psychosis patients.
    Medical condition: FIRST EPISODE DRUG-NAÏVE OF PSYCHOSIS (SCHIZOPHRENIA SPECTRUM DISORDERS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001337-40 Sponsor Protocol Number: BXCL501-105 Start Date*: 2021-10-05
    Sponsor Name:BioXcel Therapeutics, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER
    Medical condition: Subject that meets DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder, or other specified/unspecified schizophrenia spectrum and/or other psychotic disorders OR Subjec...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    20.0 10037175 - Psychiatric disorders 10039629 Schizophrenia childhood LLT
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2019-001408-39 Sponsor Protocol Number: SPON1720-19 Start Date*: 2020-03-31
    Sponsor Name:Cardiff University
    Full Title: Treating Anxiety to PrevEnt Relapse in Psychosis (TAPERS): a feasibility trial
    Medical condition: Psychosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10001022 Acute psychosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-003588-85 Sponsor Protocol Number: PSYCHIC Start Date*: 2022-01-11
    Sponsor Name:UCLouvain
    Full Title: Individualized care with antipsychotics in patients suffering from schizophrenia spectrum disorders- How to conciliate plasma concentrations, clinical response and genetic factors ?
    Medical condition: Schizophrenia, schizoaffective disorders, psychosis not otherwise specified, and dellusional disorders
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001069-32 Sponsor Protocol Number: D1449L0001 Start Date*: Information not available in EudraCT
    Sponsor Name:Psychosis Early Detection and Intervention Centre, Department for Psychiatry, UKE Hamburg
    Full Title: A prospective 8 weeks acute phase-IV study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years
    Medical condition: A prospective 8 weeks acute phase study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005734-20 Sponsor Protocol Number: R076477-SCA-3002 Start Date*: 2008-04-24
    Sponsor Name:Janssen L.P.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Flexible Dose Paliperidone ER in the Treatment of Subjects with Schizoaffective Disorder
    Medical condition: Schizoaffective disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039621 Schizoaffective disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-004391-21 Sponsor Protocol Number: A1281147 Start Date*: 2006-06-23
    Sponsor Name:Pfizer S.A.
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE (ZELDOX®, GEODON®) VS OLANZAPINE (ZYPREXA®) IN THE TREATMENT AND MAINTENANCE OF...
    Medical condition: Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004939 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GR (Prematurely Ended) DE (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000581-17 Sponsor Protocol Number: CVL-231-2002 Start Date*: 2022-10-18
    Sponsor Name:Cerevel Therapeutics, LLC
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 in Participants With Schizophreni...
    Medical condition: Patients with schizophrenia who are experiencing an acute exacerbation of psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000580-52 Sponsor Protocol Number: CVL-231-2001 Start Date*: 2022-11-02
    Sponsor Name:Cerevel Therapeutics, LLC
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231 in Participants With Schizophreni...
    Medical condition: Patients with schizophrenia who are experiencing an acute exacerbation of psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004602-17 Sponsor Protocol Number: 031-201-00186 Start Date*: 2018-03-12
    Sponsor Name:Otsuka Pharmaceutical
    Full Title: A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System with Healthcare Professionals and Adult Subjects with Schizo...
    Medical condition: Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020764-38 Sponsor Protocol Number: A8241012 Start Date*: 2010-12-14
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US
    Full Title: PHASE 2, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, 4-WEEK INPATIENT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TWO FIXED DOSES OF PF-02545920 COMPARED TO PLACEBO IN THE TREATMENT OF ...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009134 Chronic schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 30 22:57:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA